You are viewing the site in preview mode

Skip to main content

Advertisement

Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Atypical response with bone pseudoprogression in a patient receiving nivolumab for advanced cutaneous squamous cell carcinoma

Fig. 2

Bone Pseudoprogression after anti-PD1 therapy seen in 18F-FDG PET/CT’s. Sagital fused images from different 18F-FDG PET/CT’s. a Multiple focal FDG uptake in different thoracic vertebrae (T1, T3 and T7) without tomographic focal lesion (arrows), corresponding to bone metastasis. b Same corresponding thoracic bone lesions with significant increased uptake (arrowsheads), consistent with metabolic progression disease. c Metabolic resolution of most thoracic bone lesions, consistent with partial metabolic response (PMR)

Back to article page